Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Restructuring Costs (2021 - 2025)

Collegium Pharmaceutical has reported Restructuring Costs over the past 3 years, most recently at $10.9 million for Q3 2025.

  • For Q3 2025, Restructuring Costs rose 39.88% year-over-year to $10.9 million; the TTM value through Sep 2025 reached $43.5 million, up 50.89%, while the annual FY2024 figure was $33.7 million, 4.27% up from the prior year.
  • Restructuring Costs for Q3 2025 was $10.9 million at Collegium Pharmaceutical, up from $9.8 million in the prior quarter.
  • Over five years, Restructuring Costs peaked at $13.3 million in Q1 2025 and troughed at $4.6 million in Q4 2021.
  • A 3-year average of $9.0 million and a median of $9.0 million in 2024 define the central range for Restructuring Costs.
  • On a YoY basis, Restructuring Costs climbed as much as 54.11% in 2025 and fell as far as 25.49% in 2025.
  • Year by year, Restructuring Costs stood at $4.6 million in 2021, then skyrocketed by 106.92% to $9.5 million in 2024, then increased by 15.12% to $10.9 million in 2025.
  • Business Quant data shows Restructuring Costs for COLL at $10.9 million in Q3 2025, $9.8 million in Q2 2025, and $13.3 million in Q1 2025.